Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05876806
Other study ID # BROAD
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date June 20, 2023
Est. completion date March 2026

Study information

Verified date November 2023
Source Seoul St. Mary's Hospital
Contact Se Jun Park, MD, PhD
Phone 82-2-2258-6757
Email psj6936@naver.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase II, open-label, non-randomized, multi-center study of oral Dabrafenib in combination with oral Trametinib in subjects with solid tumors with BRAF V600E mutation or clinically actionable BRAF gene alterations.


Description:

Dabrafenib and trametinib combination treatment can offer a therapeutic option for patients with solid cancers harboring specific gene mutations, for whom there are no alternative treatments. Patients with BRAF V600 mutated advanced solid tumor (excluding BRAF V600E/K mutated malignant melanoma, BRAF V600E mutated non-small cell lung cancer, and BRAF V600E mutated colorectal cancer) or patients with other BRAF gene alterations that are regarded to be druggable by the KOSMOS MTB. This study is designed to determine the disease control rate (DCR) of oral Dabrafenib in combination with oral Trametinib in subjects with BRAF V600E or clinically actionable BRAF mutated cancers. Only subjects with histologically confirmed advanced disease and no available standard treatment options will be eligible for enrollment. Subjects will undergo screening assessments within 30 days prior to the start of treatment to determine their eligibility for enrollment in the study.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date March 2026
Est. primary completion date March 2026
Accepts healthy volunteers No
Gender All
Age group 19 Years and older
Eligibility Inclusion Criteria: Subjects must meet all the following criteria for study entry: 1. Patient who agreed to participate in the KOSMOS-II master observation study 2. 19 years of age or older 3. Patients with BRAF V600 mutated advanced solid tumor (excluding BRAF V600E/K mutated malignant melanoma, BRAF V600E mutated non-small cell lung cancer, and BRAF V600E mutated colorectal cancer) 4. Patients with other BRAF gene alterations that are regarded to be actionable by the KOSMOS MTB 5. Disease progression after = 1-prior line of systemic treatment and no standard treatment option 6. ECOG performance status score 0-2 7. Life expectancy of > 3 months 8. Measurable or evaluable disease according to RECIST version 1.1 9. Ability to take oral medications 10. Adequate bone marrow and organ function 11. Patients who voluntarily decided to participate after understanding this clinical trial, and signed a written informed consent Exclusion Criteria: Subjects who meet any of the following criteria will be excluded from study entry: 1. Prior treatment with a BRAF inhibitor (including, but not limited to, dabrafenib, vemurafenib, encorafenib) or MEK inhibitor (including, but not limited to, trametinib, binimetinib, selumetinib, cobimetinib) or ERK inhibitor (including, but not limited to, ravoxertinib, ulixertinib, CC-90003, MK-8353) 2. History of malignancies with confirmed activating RAS mutation. 3. Hypersensitivity to the active ingredients and additives of investigational product. 4. Presence of any unresolved =Grade 2 (per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0) toxicity from previous anti-cancer therapy at the time of enrollment. (Except toxicities which are not clinically significant such as alopecia, skin discoloration, and neuropathy). 5. Any anti-cancer treatment (local treatment, chemotherapy, immunotherapy, targeted therapy) within 2 weeks prior to the start of study treatment. 6. Prior major surgery less than 14 days before enrollment. Any surgery-related AE must have been resolved before enrollment. 7. Prior radiotherapy less than 14 days before enrollment, except for ATC (radiotherapy is not permitted within 7 days before enrollment). 8. Known additional malignancy that is progressing or has required active treatment within the past 3 years. (Patient with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma is potentially eligible). 9. Presence of central nervous system metastases that are symptomatic or untreated or not stable for =3 months or requiring corticosteroids. 10. Symptomatic or untreated leptomeningeal or spinal cord compression. Subjects who have been previously treated for these conditions are asymptomatic and currently not taking corticosteroids before enrollment, is permitted. 11. Current evidence of cardiovascular risk including any of the following: - Left ventricular ejection fraction (LVEF) below the institutional lower limit of normal - QT interval corrected for heart rate using Bazett's formula = 480 msec - Clinically significant uncontrolled arrhythmias - Moderate valvular thickening documented by echocardiography - Presence of intra-cardiac defibrillators - Acute coronary syndromes (including myocardial infarction and unstable angina) which required coronary angioplasty or stenting within 6 months before enrollment - Congestive heart failure = Class II as defined by New York Heart Association 12. Current evidence or history of retinal vein occlusion 13. Pregnant or lactating women 14. Patients who do not consent to adequate contraception throughout the study period - Women of childbearing potential should use effective contraception* until 16 weeks after the last investigational product administration - Male patients who have not undergone a vasectomy must consent to the use of appropriate contraception* and are prohibited from providing sperm for up to 16 weeks after administration of the last investigational product * Appropriate contraception: hormonal contraceptives (subcutaneous formulas, injections, oral contraceptives, etc.), intrauterine devices (IUD, Intra Uterine Device or IUS, Intra Uterine System), sterilization by participants or participant's partner (vasectomy, tubal ligation, etc.); Double blocking (a method that uses a combination of blocking methods, such as using a cervical cap or a contraceptive diaphragm with a male condom) 15. Active infection such as hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) - For HBsAg is positive, and HBV DNA = LLOQ, enrollment of the subject can be considered. - If the patient with chronic hepatitis B who are HBsAg positive and HBV DNA positive has been taking antiviral drugs for more than 3 months, enrollment of the subject can be considered at the investigator's discretion. - For IgG anti-HBc is positive (a history of HBV infection) and HBV DNA = LLOQ, enrollment of the subject can be considered. - For Anti-HCV Ab is positive, and HCV RNA = LLOQ, enrollment of the subject can be considered. 16. Acute/chronic medical or psychiatric abnormalities 17. The investigator judges that it is not appropriate to participate in this study for else reasons.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Dabrafenib
Dabrafenib is a 150 mg twice daily capsule administered orally on a continuous basis
Trametinib
Trametinib is a 2 mg once daily tablet administered orally on a continuous basis.

Locations

Country Name City State
Korea, Republic of Seoul St. Mary's Hospital, The Catholic University of Korea Seoul

Sponsors (1)

Lead Sponsor Collaborator
Se Jun Park

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Disease Control Rate (DCR) Disease control Rate (DCR) is defined as the proportion of subjects with objective evidence of complete response (CR), partial response (PR), or stable disease (SD). From study treatment start date until first documented complete response, partial response or stable disease, assessed up to 36 months
Secondary Overall Survival (OS) Overall Survival (OS) is defined as the time from first dose until death due to any cause. From study treatment start date until date of of death from any cause, assessed up to 36 months
Secondary Progression Free Survival (PFS) Progression Free Survival (PFS) is defined as the interval between the first dose of study treatment and earlier date of first radiologically documented progression or death due to any cause. From study treatment start date until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to 36 months
Secondary Objective Response Rate (ORR) Overall Response Rate (ORR) is defined as the percentage of participants with a confirmed overall response by investigator assessment as defined by the pre-specified response criteria. From study treatment start date until first documented complete response or partial response, assessed up to 36 months
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients